Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Amortizatization of Intangibles (2021 - 2025)

Historic Amortizatization of Intangibles for NovaBay Pharmaceuticals (NBY) over the last 11 years, with Q3 2025 value amounting to $33000.0.

  • NovaBay Pharmaceuticals' Amortizatization of Intangibles fell 7724.14% to $33000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $126000.0, marking a year-over-year decrease of 9126.21%. This contributed to the annual value of $874000.0 for FY2024, which is 4828.4% down from last year.
  • NovaBay Pharmaceuticals' Amortizatization of Intangibles amounted to $33000.0 in Q3 2025, which was down 7724.14% from $37000.0 recorded in Q2 2025.
  • NovaBay Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $571000.0 during Q4 2023, with a 5-year trough of $3000.0 in Q4 2024.
  • For the 5-year period, NovaBay Pharmaceuticals' Amortizatization of Intangibles averaged around $137800.0, with its median value being $90000.0 (2022).
  • Data for NovaBay Pharmaceuticals' Amortizatization of Intangibles shows a peak YoY increase of 71842.11% (in 2024) and a maximum YoY decrease of 9947.46% (in 2024) over the last 5 years.
  • Over the past 5 years, NovaBay Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $60000.0 in 2021, then soared by 51.67% to $91000.0 in 2022, then skyrocketed by 527.47% to $571000.0 in 2023, then crashed by 99.47% to $3000.0 in 2024, then skyrocketed by 1000.0% to $33000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $33000.0 for Q3 2025, versus $37000.0 for Q2 2025 and $53000.0 for Q1 2025.